Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 15:24:13 16/05/2024 BST 		5-day change 1st Jan Change
2.6 ILa -3.70% Intraday chart for Can-Fite BioPharma Ltd. -3.70% 0.00%
05-12 Transcript : Can-Fite BioPharma Ltd. - Special Call
05-09 Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study
CI
Can-Fite Biopharma Ltd. Announces Clinical Update
CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs
CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office
CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial
CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action
CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson
CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients
CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson
CI
Can-Fite Biopharma Ltd. Provides Business Update
CI
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal
CI
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence
CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CANF Stock
  4. News Can-Fite BioPharma Ltd.
  5. Highlights